A phase 3 clinical trial demonstrates the efficacy of olezarsen in reducing plasma triglycerides and acute pancreatitis episodes in patients with familial chylomicronemia syndrome.
Plozasiran, a first-in-class RNA interference therapeutic, reduced triglycerides by 80% and lowered the risk of acute pancreatitis by 83% in patients with familial chylomicronemia syndrome (FCS), earning...
One-third of US adults have elevated low-density lipoprotein cholesterol levels, a condition that is most often diagnosed and treated in primary care. Appropriate screening helps identify these patients...
